Dr. Qian received his PhD in Toxicology in the Department of Environmental Health Sciences at the University of Georgia in December 2012. After graduation, he worked as a postdoctoral fellow and scientist in the Department of Hematology and Medical Oncology at Emory University. Dr. Qian was appointed as an Assistant Professor in the Department of Cellular and Molecular Biology at the University of Texas Health Science Center at Tyler in July 2019. He has published more than 30 peer-reviewed papers and serves as a reviewer for more than 10 scientific journals. Dr. Qian is an active member of the Society of Toxicology. He has mentored many undergraduate and graduate students, and visiting scholars from China, Malaysia, Korea, Burkina Faso, and Uganda.

Dr. Qian’s current research focuses on the novel immune and inflammatory molecules and pathways that are critical for the development of pulmonary fibrosis, pleural fibrosis, lung cancer, and metabolic diseases. His research interest lies in posttranslational modification, cell phenotypic modulation, invasion and metastasis, apoptosis, druggable target discovery, biomarker development, and chemoprevention with natural compounds.

Education & Training

Assistant Scientist, Emory University, 2019
Postdoctoral Fellow, Emory University, 2018
PhD, The University of Georgia, Toxicology, 2012
MS, Fudan University, Toxicology, China, 2007
BS, Jining Medical College, Preventive Medicine, China, 2004

Courses Taught

BIOT5132 - Critical Reading II, University of Texas Health Science Center at Tyler

Research Interest

Pulmonary and pleural fibrosis
Posttranslational modification
Cell phenotypic modulation
Invasion and metastasis
Molecular biomarkers and chemoprevention

Publication Highlights

Zang H., Qian G., Zong D., Fan S., Owonikoko T.K., Ramalingam S.S., and Sun S-Y. (2020). Overcoming acquired resistance of EGFR mutant NSCLC cells to osimertinib by combining osimertinib with the HDAC inhibitor, panobinostat (LBH589). Cancer. [Epub ahead of print] Deng L.*, Qian G.*, Zhang S., Lesinski, G., Owonikoko T.W., Ramalingam S.S., and Sun S-Y. (2019) Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization likely by promoting β-TrCP degradation. Oncogene. 38(35):6270-6282. * Equal contribution Zhang S., Qian G., Zhang Q.Q., Yao Y., Wang D., Chen Z.G., Wang L.J., Chen M., Sun S-Y. (2019) mTORC2 Suppresses GSK3-Dependent Snail Degradation to Positively Regulate Cancer Cell Invasion and Metastasis.Cancer Res.79(14):3725-3736.
Qian G., Yao W., Zhang S., Bajpai R., Hall W.D., Shanmugam M., Lonial S., and Sun S-Y. (2018). Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy. Cancer Lett. 435:44-54.
Oh Y-T., Qian G., Deng J., and Sun S-Y. (2018). Monocyte Chemotactic Protein-induced Protein-1 Enhances DR5 Degradation and Negatively Regulates DR5 Activation-induced Apoptosis through its Deubiquitinase Function. Oncogene. 37(25):3415-3425.